Cystic Fibrosis Point of Personalized Detection (CFPOPD): An Interactive Web Application

Overview

Journal JMIR Med Inform

Publisher JMIR Publications

Specialty Medical Informatics

Date 2020 Dec 16

PMID 33325834

Citations 2

Authors

Christopher Wolfe

Teresa Pestian

Emrah Gecili

Weiji Su

Ruth H Keogh

John P Pestian

Michael Seid

Peter J Diggle

Assem Ziady

John Paul Clancy

Daniel H Grossoehme

Rhonda D Szczesniak

Cole Brokamp

Affiliations

Soon will be listed here.

Abstract

Background: Despite steady gains in life expectancy, individuals with cystic fibrosis (CF) lung disease still experience rapid pulmonary decline throughout their clinical course, which can ultimately end in respiratory failure. Point-of-care tools for accurate and timely information regarding the risk of rapid decline is essential for clinical decision support.

Objective: This study aims to translate a novel algorithm for earlier, more accurate prediction of rapid lung function decline in patients with CF into an interactive web-based application that can be integrated within electronic health record systems, via collaborative development with clinicians.

Methods: Longitudinal clinical history, lung function measurements, and time-invariant characteristics were obtained for 30,879 patients with CF who were followed in the US Cystic Fibrosis Foundation Patient Registry (2003-2015). We iteratively developed the application using the R Shiny framework and by conducting a qualitative study with care provider focus groups (N=17).

Results: A clinical conceptual model and 4 themes were identified through coded feedback from application users: (1) ambiguity in rapid decline, (2) clinical utility, (3) clinical significance, and (4) specific suggested revisions. These themes were used to revise our application to the currently released version, available online for exploration. This study has advanced the application's potential prognostic utility for monitoring individuals with CF lung disease. Further application development will incorporate additional clinical characteristics requested by the users and also a more modular layout that can be useful for care provider and family interactions.

Conclusions: Our framework for creating an interactive and visual analytics platform enables generalized development of applications to synthesize, model, and translate electronic health data, thereby enhancing clinical decision support and improving care and health outcomes for chronic diseases and disorders. A prospective implementation study is necessary to evaluate this tool's effectiveness regarding increased communication, enhanced shared decision-making, and improved clinical outcomes for patients with CF.

Citing Articles

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy.

Zhou G, Wang Z, Palipana A, Andrinopoulou E, Afonso P, McPhail G Respir Res. 2024; 25(1):187.

PMID: 38678203 PMC: 11056050. DOI: 10.1186/s12931-024-02794-2.

Cystic Fibrosis Point of Personalized Detection (CFPOPD): An Interactive Web Application.

Wolfe C, Pestian T, Gecili E, Su W, Keogh R, Pestian J JMIR Med Inform. 2020; 8(12):e23530.

PMID: 33325834 PMC: 7773511. DOI: 10.2196/23530.

References

Simpao A, Ahumada L, Martinez B, Cardenas A, Metjian T, Sullivan K . Design and Implementation of a Visual Analytics Electronic Antibiogram within an Electronic Health Record System at a Tertiary Pediatric Hospital. Appl Clin Inform. 2018; 9(1):37-45. PMC: 5801883. DOI: 10.1055/s-0037-1615787. View

Szczesniak R, Heltshe S, Stanojevic S, Mayer-Hamblett N . Use of FEV in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher. J Cyst Fibros. 2017; 16(3):318-326. PMC: 5420487. DOI: 10.1016/j.jcf.2017.01.002. View

Diggle P, Sousa I, Asar O . Real-time monitoring of progression towards renal failure in primary care patients. Biostatistics. 2014; 16(3):522-36. DOI: 10.1093/biostatistics/kxu053. View

Kaiser T, Laireiter A . DynAMo: A Modular Platform for Monitoring Process, Outcome, and Algorithm-Based Treatment Planning in Psychotherapy. JMIR Med Inform. 2017; 5(3):e20. PMC: 5544897. DOI: 10.2196/medinform.6808. View

Saunders B, Kitzinger J, Kitzinger C . Anonymising interview data: challenges and compromise in practice. Qual Res. 2015; 15(5):616-632. PMC: 4582834. DOI: 10.1177/1468794114550439. View

Szczesniak R, Su W, Brokamp C, Keogh R, Pestian J, Seid M . Dynamic predictive probabilities to monitor rapid cystic fibrosis disease progression. Stat Med. 2019; 39(6):740-756. PMC: 7028099. DOI: 10.1002/sim.8443. View

Wolfe C, Pestian T, Gecili E, Su W, Keogh R, Pestian J . Cystic Fibrosis Point of Personalized Detection (CFPOPD): An Interactive Web Application. JMIR Med Inform. 2020; 8(12):e23530. PMC: 7773511. DOI: 10.2196/23530. View

Luz C, Berends M, Dik J, Lokate M, Pulcini C, Glasner C . Rapid Analysis of Diagnostic and Antimicrobial Patterns in R (RadaR): Interactive Open-Source Software App for Infection Management and Antimicrobial Stewardship. J Med Internet Res. 2019; 21(6):e12843. PMC: 6592398. DOI: 10.2196/12843. View

Szczesniak R, McPhail G, Duan L, Macaluso M, Amin R, Clancy J . A semiparametric approach to estimate rapid lung function decline in cystic fibrosis. Ann Epidemiol. 2013; 23(12):771-7. DOI: 10.1016/j.annepidem.2013.08.009. View

10.

Kaplan S, Greenfield S, Gandek B, Rogers W, Ware Jr J . Characteristics of physicians with participatory decision-making styles. Ann Intern Med. 1996; 124(5):497-504. DOI: 10.7326/0003-4819-124-5-199603010-00007. View

11.

Caban J, Gotz D . Visual analytics in healthcare--opportunities and research challenges. J Am Med Inform Assoc. 2015; 22(2):260-2. PMC: 11737105. DOI: 10.1093/jamia/ocv006. View

12.

Harun S, Wainwright C, Klein K, Hennig S . A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. Paediatr Respir Rev. 2016; 20:55-66. DOI: 10.1016/j.prrv.2016.03.002. View

13.

Feller D, Burgermaster M, Levine M, Smaldone A, Davidson P, Albers D . A visual analytics approach for pattern-recognition in patient-generated data. J Am Med Inform Assoc. 2018; 25(10):1366-1374. PMC: 6188507. DOI: 10.1093/jamia/ocy054. View

14.

Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen H, Pressler T, Smyth R . Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax. 2012; 67(10):860-6. PMC: 3446776. DOI: 10.1136/thoraxjnl-2011-200953. View

15.

Szczesniak R, Brokamp C, Su W, McPhail G, Pestian J, Clancy J . Improving Detection of Rapid Cystic Fibrosis Disease Progression-Early Translation of a Predictive Algorithm Into a Point-of-Care Tool. IEEE J Transl Eng Health Med. 2019; 7:2800108. PMC: 6368437. DOI: 10.1109/JTEHM.2018.2878534. View

16.

Solomon G, Marshall S, Ramsey B, Rowe S . Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors. Pediatr Pulmonol. 2015; 50 Suppl 40:S3-S13. PMC: 4620567. DOI: 10.1002/ppul.23240. View

17.

Caron A, Chazard E, Muller J, Perichon R, Ferret L, Koutkias V . IT-CARES: an interactive tool for case-crossover analyses of electronic medical records for patient safety. J Am Med Inform Assoc. 2016; 24(2):323-330. PMC: 5391728. DOI: 10.1093/jamia/ocw132. View

18.

Schechter M, Schmidt H, Williams R, Norton R, Taylor D, Molzhon A . Impact of a program ensuring consistent response to acute drops in lung function in children with cystic fibrosis. J Cyst Fibros. 2018; 17(6):769-778. DOI: 10.1016/j.jcf.2018.06.003. View

19.

Salvatore D, Buzzetti R, Mastella G . An overview of international literature from cystic fibrosis registries. Part 5: Update 2012-2015 on lung disease. Pediatr Pulmonol. 2016; 51(11):1251-1263. DOI: 10.1002/ppul.23473. View

20.

Heisler M, Bouknight R, Hayward R, Smith D, Kerr E . The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management. J Gen Intern Med. 2002; 17(4):243-52. PMC: 1495033. DOI: 10.1046/j.1525-1497.2002.10905.x. View